Navigation Links
Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting
Date:9/8/2011

ere evaluable. In the 71% of patients with MP joints that achieved clinical success and did not recur through three years, the mean degree of contracture was 37.6 degrees at pre-treatment baseline and 2.8 degrees at three years. In the 21% of MP joints that achieved clinical success and did recur through three years, the mean degree of contracture was 40.1 degrees at pre-treatment baseline and 36.7 degrees at three years. Eight percent of patients with MP joints received medical or surgical intervention and were therefore not included in this analysis. Similar trends were seen through three years with evaluable patients with Proximal Interphalangeal (PIP) joints that achieved clinical success.

(Photo: http://photos.prnewswire.com/prnh/20110908/PH64581)

These data will be available starting September 8 via an e-poster from Dr. Thomas Kaplan et al. that is entitled "Year 3 recurrence data for the use of CCH in the treatment of Dupuytren's Contracture with a palpable cord." E-posters will be available during the entire ASSH meeting via the kiosks in the meeting hall or online at http://tinyurl.com/AM11eposters. A complete analysis of the three-year recurrence data is pending and the Company is seeking publication of full results in an appropriate medical journal.

About Dupuytren's contracture

Dupuytren's contracture is a chronic condition that affects the connective tissue that lies beneath the skin in the palm. The disease is progressive in nature. Typically, skin pits then nodules develop in the palm as collagen deposits accumulate. As the disease progresses, the collagen deposits form a cord that stretches from the palm of the hand to the base of the finger. Once this cord develops, the patient's fingers contract and the function of the hand is impaired. The incidence of Dupuytren's disease, inclusive of pits, nodules a
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals Announces Positive Data from Commercial Patient Chart Review in E-posters at ASSH Meeting
2. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
3. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
4. Auxilium Pharmaceuticals Announces Investor Event to Occur at 2011 ASSH Meeting on September 9, 2011
5. Auxilium Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference
6. Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
7. Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011
8. Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytrens Contracture
9. Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
11. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), ... equipment for all forms of sports, including extreme motor ... brace, announced today that the UISP Lega Motociclismo Lombardia, ... all riders to wear a neck brace during its ...
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine ... announced the business and development progress at its Jiangchuan ... the September 2014 JCM application (No. 51268) for the ...
(Date:1/22/2015)... Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... on Omega-3 therapies for cardiovascular disease and overall health is ... accomplishments in 2014 and its outlook for 2015 from the ... Shareholders, We would like to take this opportunity ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... On March 10-11, 2010 , the Joint Advisory Committees of the U.S. Food and ... Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products ... ... ...
... With patent expiration a looming concern across the bio-pharmaceutical industry, new product commercialization efforts have taken on increased importance. ... pressures of meeting timelines and delivering commercial insights. , ... ... ...
Cached Medicine Technology:AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 2AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 3AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 4AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 5AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 6AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 7AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 8Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 2Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 3Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 4
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... scientists at Beth Israel Deaconess Medical Center (BIDMC) have ... part of their 2009 Creativity Awards program, which supports ... prostate cancer. , The one-year awards were made ... with BIDMC the only institution in New England to ...
... Donation Are CommonRICHMOND, Va., April 14 ... tissue donors is rising, the registry still only includes ... card issued by Donate Life America this year. ... percent of people want their decision to donate honored, ...
... Alliance Medical Plans, Inc., a leading provider-sponsored health insurer, ... has announced an innovative Fracture Protection Pilot Program, in ... makers of Actonel, a prescription drug for the treatment ... the Alliance for Better Bone Health will cover the ...
... (Nasdaq: ROCM ) will announce quarterly results after ... Company will then hold a quarterly conference call to discuss ... p.m. central time (5:00 p.m. eastern time).This call is being ... website at www.rocm.com . To listen ...
... Surgeon Dr. Robert Schwartz recommends VASER Lipo System with ... these ground breaking fat transfer procedures.DALLAS, April 14 ... Surgeons (ASPS) Fat Graft Task Force gives U.S. plastic ... Schwartz, a green light to use autologous fat transfer ...
... Arbor, MI--Patients with a rare, blinding eye disease saw ... their immune systems, according to researchers at the University ... (AIR) is difficult to diagnose, the biggest challenge now ... can benefit from treatment. , In a review of ...
Cached Medicine News:Health News:BIDMC scientists receive creativity awards from Prostate Cancer Foundation 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 3Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 2Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 3Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 4Health News:Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009 2Health News:U.S. Plastic Surgeons Get Green Light for New Era of Fat Transfer Procedures. 2Health News:Study reports success in treating a rare retinal disorder 2
... the 17 million echocardiograms performed annually ... DEFINITY increases the power of echocardiography, ... than with echo alone. As a ... for many patientsby illuminating the heart, ...
... Launched in 1996, VISIPAQUE is the only ... With an osmolality equal to that of blood, ... VISIPAQUE is also the only contrast medium formulated ... to blood. In 1997, VISIPAQUE received FDA approval ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
... Padgett's commitment to quality and innovation has ... product developments: The Model C is an ... required for instruments in burn care surgery. ... constructed with the same dedication to quality, ...
Medicine Products: